We recently published a list of Jim Cramer Commented On These 6 Stocks Recently. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY)) stands against other stocks that Jim Cramer commented discussed recently.

In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer continued to warn users to not trust billionaires. His remarks built on an earlier show, where he had shared that “you can’t make money listening to a billionaire because they already have made money.”

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Eli Lilly and Company by 0.6% during the fourth quarter. Vanguard Group ...

Whatever you think of Donald Trump’s tariff policies, one fact stands out: companies are looking to invest more in the United States. They want to avoid the negative impacts of tariffs on their business.

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants later this year.

Eli Lilly and Company said Wednesday they plan to build new pharmaceutical manufacturing sites in the United States.

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY) has produced over the past five years. Let's figure out how Lilly could perform through the end of the decade, and decide whether it's still worth investing in the stock.

Eli Lilly said it plans to build three new plants in the United States to make the key ingredients used in pharmaceuticals, part of a doubling of its investment in manufacturing.

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture knockoff versions of Eli Lilly's tirzepatide while a lawsuit plays out. | A Texas court has rejected a request by compounders to extend their ability to manufacture knockoff versions of Eli Lilly's tirzepatide while a lawsuit plays out.

Following the results of a study by USC Annenberg Inclusion Initiative demonstrating the lack of adequate representation of those with health conditions in film and television, Eli Lilly and Company is partnering with leading content creators and production companies,

Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.